TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
AI in Drug DiscoveryThe healthcare AI sector is poised for significant expansion in 2026, with transformative impacts expected across clinical applications, value-based care models, and data infrastructure. Bessemer’s insights underscore a surge in AI-driven innovation that could reshape patient care and health system efficiencies.
TCB TeamJan 23, 2026
Healthcare InvestmentThe world of brain science is experiencing unprecedented growth and interest from investors and innovators alike. Enabled by breakthroughs in biomarkers, brain mapping technologies, and AI applications, the field is moving rapidly. This in-depth analysis explores the current landscape of neuroscience investment and innovation, highlighting key trends and insights from the recent JPM26 conference.
TCB TeamJan 22, 2026
Regulatory & PolicyAfter previously being stymied, elements of a bipartisan health care package have reemerged in Congressional discussions. Central to the proposal are updated regulations on pharmacy benefit managers and strategies to mitigate drug pricing inflation, reflecting the complexity and urgency in reforming the U.S. health care system.
TCB TeamJan 20, 2026
Biotech InnovationA recent study analyzing diabetes management outcomes has provided compelling evidence that bariatric surgery delivers better control of type 2 diabetes than GLP-1 medications irrespective of patients’ income levels. This insight carries significant implications for the approach to diabetes care and healthcare policy.
TCB TeamJan 20, 2026
Biopharmaceutical IndustryGalapagos, a biotech company with decades of history, has faced turbulent times in recent years. The appointment of Henry Gosebruch as CEO signals a turning point with significant resources at his disposal to redirect the company's trajectory. This article explores the challenges faced by Galapagos, the new leadership’s outlook, and the broader context of the biopharmaceutical industry as it navigates through evolving market dynamics.
TCB TeamJan 19, 2026
Healthcare InvestmentThe biopharmaceutical sector is witnessing sustained investor enthusiasm as more companies prepare for public offerings. Insights into current IPO trends reflect the evolving state of the market and investor confidence.
TCB TeamJan 19, 2026
Biopharmaceutical IndustryNovo Nordisk has marked a notable milestone with the swift adoption of its oral Wegovy drug, signaling a key moment in the competitive landscape of GLP-1 therapies, although rival Eli Lilly leads in sales.
TCB TeamJan 19, 2026
Biopharmaceutical IndustryThe U.S. life sciences sector exhibited cautious optimism at the end of 2025, with job market indicators suggesting a meaningful shift towards stability. This review explores the key takeaways from BioSpace’s latest quarterly report and what they imply for industry employment trends and economic health.
TCB TeamJan 19, 2026
Regulatory & PolicyThe 2026 J.P. Morgan Healthcare Conference illuminated critical themes in biotech regulatory affairs. Companies conveyed a collective push for harmony with the FDA concerning clinical trial protocols and expedited approval pathways. Nonetheless, the conference also underscored ongoing regulatory complexities through cases like Atara’s recent therapy denial.
TCB TeamJan 19, 2026
Medical TechnologyAllergy diagnosis often faces challenges due to incomplete histories and insufficient testing. New approaches focus on capturing detailed symptomatology and applying thorough testing to close this gap, streamline resource use, and enhance safety.
TCB TeamJan 18, 2026
Healthcare InvestmentRecent insights emphasize that programs which blend personalized human interaction alongside effective use of technology outperform those relying on technology alone in improving healthcare member engagement, quality outcomes, and retention.
TCB TeamJan 18, 2026
Healthcare InvestmentThe COVID-19 pandemic left profound emotional and psychological scars on healthcare workers and communities. This opinion piece explores the lingering despair and calls attention to the lack of public accountability and outrage regarding the pandemic's management.
TCB TeamJan 18, 2026